- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03898830
Eon™ FR Clinical Study Protocol 1064
May 16, 2020 updated by: Dominion Aesthetic Technologies, Inc.
A Prospective, Controlled, Standardized, Multi-center, Single-treatment, Single-arm Evaluation of the Eon™ FR 1064 nm Device to Reduce Abdominal Fat With a 12-week Observation Interval to Assess Safe Fat Reduction
This study evaluates the treatment of subjects with the eon™ FR 1064 nm device in a single session to thermally induce apoptosis in adipose tissue.
Study Overview
Detailed Description
This study evaluates the treatment of subjects between 18-60 with the eon™ FR 1064 nm device in a single session to thermally induce apoptosis in adipose tissue in the abdomen.
Study Type
Interventional
Enrollment (Actual)
36
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
California
-
Sacramento, California, United States, 95816
- Laser & Skin Surgery Center of Northern
-
-
Florida
-
Altamonte Springs, Florida, United States, 32701
- Fiala Aesthetics
-
Miami, Florida, United States, 33173
- Miami Dermatology & Laser Research
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
19 years to 58 years (Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Body Mass Index (BMI) of 30 kg/m2 or less.
- Healthy male or female between the ages of 21 and 60.
- Had, at least 25 mm thickness adipose tissue on abdomen.
- Able to read, understand and sign the Informed Consent Form (ICF).
- Willing and able to adhere to the treatment and follow-up schedule and post-treatment care instructions.
- Willing to have limited sun exposure for the duration of the study, including the follow-up period.
- Willing to have photographs and ultrasound measurements taken of the treated area, which could be used de-identified in evaluations and could be used de-identified in presentations and/or publications.
- Female subjects were either post-menopausal, surgically sterilized, or used a medically acceptable form of birth control during the entire course of the study.
- Female subjects with child bearing potential were willing to take a urine pregnancy test and the result must be negative.
- Agreed to maintain their current diet and exercise habits and not be specifically trying to lose weight.
Exclusion Criteria:
- Aesthetic fat reduction procedure in the treatment area within the previous year.
- Age less than 21 or greater than 60 years old.
- Female subject pregnant or planning to become pregnant during the study duration,
- Had an infection, dermatitis or a rash in the treatment area.
- Had tattoos or jewelry in the treatment area.
- Had a history of keloid scarring, hypertrophic scarring or of abnormal wound healing.
- Had a history of immunosuppression/immune deficiency disorders or currently using immunosuppressive medications.
- Had a history of a known bleeding disorder.
- Had a known photosensitivity to the study laser wavelength, history of ingesting. medications known to induce photosensitivity, or history of seizure disorders due to light.
- Had known collagen, vascular disease or scleroderma.
- Underwent a surgery or procedure in the treatment area within 6 months of treatment, which is still healing.
- Had underwent a fat reduction procedure in the treatment area within the past 12 months.
- Had a significant concurrent illness, such as insulin-dependent diabetes, peripheral vascular disease or peripheral neuropathy.
- Underwent systemic chemotherapy for the treatment of cancer.
- Used gold therapy for disorders such as rheumatologic disease or lupus.
- Participated in a study of another device or drug within three months prior to enrollment or during the study.
- As per the investigator's discretion, the subject had any physical or mental condition which might make it unsafe for the subject to participate in this study.
- Concurrent use of steroids or secondary rheumatoid drugs.
- Prior liposuction or a tummy tuck in the study area.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: eon™ FR 1064 nm device
Patient will be treated with the eon™ FR 1064 nm device
|
The subject treatment area - abdomen, was treated with the 1064 nm wavelength laser.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Photographic Evaluations as a Measure of Effectiveness
Time Frame: 12 weeks
|
Photographs of the treatment area will be obtained at baseline and 12 weeks post treatment and be evaluated by blinded independent readers to correctly identify pre-treatment (baseline) photographs compared to 12 weeks post treatment photographs in order to determine effectiveness of device.
|
12 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Circumferential Measurements to Evaluate Reduction in Adipose Layer Thickness
Time Frame: 12 weeks
|
Circumferential measurements of the treatment area will be completed and evaluated in comparison to the baseline results to determine the reduction in adipose layer thickness.
|
12 weeks
|
Ultrasound Measurement to Evaluate Reduction in Adipose Layer Thickness
Time Frame: 12 weeks
|
Ultrasound of the treatment area will be performed and evaluated in comparison to the baseline results to determine the reduction in adipose layer thickness.
|
12 weeks
|
Subject Questionnaire to determine Subject Satisfaction
Time Frame: 12 weeks
|
Subject Questionnaires will be completed by subjects at the end of study to determine the subject satisfaction with procedure.
|
12 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
December 8, 2018
Primary Completion (Actual)
March 22, 2019
Study Completion (Actual)
March 22, 2019
Study Registration Dates
First Submitted
March 28, 2019
First Submitted That Met QC Criteria
March 29, 2019
First Posted (Actual)
April 2, 2019
Study Record Updates
Last Update Posted (Actual)
May 19, 2020
Last Update Submitted That Met QC Criteria
May 16, 2020
Last Verified
May 1, 2020
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- D0000000135
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
No
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
Yes
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Fat Disorder
-
Zeltiq AestheticsCompleted
-
Zeltiq AestheticsCompleted
-
Zeltiq AestheticsCompleted
-
Zeltiq AestheticsCompleted
-
Zeltiq AestheticsCompletedBody Fat DisorderUnited States
-
Zeltiq AestheticsCompleted
-
Zeltiq AestheticsCompleted
Clinical Trials on eon™ FR 1064 nm device
-
Dominion Aesthetic Technologies, Inc.Completed
-
Dominion Aesthetic Technologies, Inc.Completed
-
Medtronic Neurovascular Clinical Affairsev3 InternationalCompleted
-
Gregory W AlbersMedical University of South Carolina; National Institute of Neurological Disorders... and other collaboratorsTerminatedCerebral Infarction | Stroke, AcuteUnited States